BR0312030A - Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii - Google Patents

Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii

Info

Publication number: BR0312030A
Authority: BR; Brazil
Prior art keywords: angiotensin; combination; receptor antagonists; pde5 inhibitors; pde5
Prior art date: 2002-06-26

Application number

BR0312030-9A

Other languages

English (en)

Portuguese (pt)

Inventor

David Nathan Abraham Fox

Bernadette Hughes

Original Assignee

Pfizer

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-06-26

Filing date

2003-06-16

Publication date

2005-03-22

2003-06-16 Application filed by Pfizer filed Critical Pfizer

2005-03-22 Publication of BR0312030A publication Critical patent/BR0312030A/pt

Links

239000002333 angiotensin II receptor antagonist Substances 0.000 title abstract 3
229940123333 Phosphodiesterase 5 inhibitor Drugs 0.000 title abstract 2
239000002590 phosphodiesterase V inhibitor Substances 0.000 title abstract 2
ZOOGRGPOEVQQDX-KHLHZJAASA-N cyclic guanosine monophosphate Chemical compound C([C@H]1O2)O[P@](O)(=O)O[C@@H]1[C@H](O)[C@H]2N1C(N=C(NC2=O)N)=C2N=C1 ZOOGRGPOEVQQDX-KHLHZJAASA-N 0.000 abstract 2
101100189582 Dictyostelium discoideum pdeD gene Proteins 0.000 abstract 1
206010020772 Hypertension Diseases 0.000 abstract 1
101150098694 PDE5A gene Proteins 0.000 abstract 1
102000011016 Type 5 Cyclic Nucleotide Phosphodiesterases Human genes 0.000 abstract 1
108010037581 Type 5 Cyclic Nucleotide Phosphodiesterases Proteins 0.000 abstract 1
229940126317 angiotensin II receptor antagonist Drugs 0.000 abstract 1
102100029175 cGMP-specific 3',5'-cyclic phosphodiesterase Human genes 0.000 abstract 1
239000003112 inhibitor Substances 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Pharmacology & Pharmacy (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Bioinformatics & Cheminformatics (AREA)
Engineering & Computer Science (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Cardiology (AREA)
Heart & Thoracic Surgery (AREA)
Epidemiology (AREA)
Diabetes (AREA)
Endocrinology (AREA)
Urology & Nephrology (AREA)
Hospice & Palliative Care (AREA)
Hematology (AREA)
Obesity (AREA)
Emergency Medicine (AREA)
Reproductive Health (AREA)
Vascular Medicine (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

BR0312030-9A 2002-06-26 2003-06-16 Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii BR0312030A (pt)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
GBGB0214784.1A GB0214784D0 (en)	2002-06-26	2002-06-26	Novel combination
PCT/IB2003/002657 WO2004002461A2 (fr)	2002-06-26	2003-06-16	Nouvelle combinaison

Publications (1)

Publication Number	Publication Date
BR0312030A true BR0312030A (pt)	2005-03-22

Family

ID=9939342

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
BR0312030-9A BR0312030A (pt)	2002-06-26	2003-06-16	Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii

Country Status (20)

Country	Link
EP (1)	EP1524996A2 (fr)
JP (1)	JP2005531627A (fr)
KR (1)	KR20050013156A (fr)
CN (1)	CN1662257A (fr)
AR (1)	AR040337A1 (fr)
AU (1)	AU2003242895A1 (fr)
BR (1)	BR0312030A (fr)
CA (1)	CA2491002A1 (fr)
GB (1)	GB0214784D0 (fr)
GT (1)	GT200300124A (fr)
MX (1)	MXPA04012569A (fr)
NO (1)	NO20050400L (fr)
PA (1)	PA8575501A1 (fr)
PE (1)	PE20040868A1 (fr)
PL (1)	PL375079A1 (fr)
RU (1)	RU2004136276A (fr)
TW (1)	TW200404546A (fr)
UY (1)	UY27863A1 (fr)
WO (1)	WO2004002461A2 (fr)
ZA (1)	ZA200409532B (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US7019010B2 (en)	2001-09-27	2006-03-28	Novertis Ag	Combinations
EP1528380A4 (fr) *	2002-07-26	2009-12-09	Olympus Corp	Systeme de traitement d'images
US20060205733A1 (en) *	2004-08-26	2006-09-14	Encysive Pharmaceuticals	Endothelin a receptor antagonists in combination with phosphodiesterase 5 inhibitors and uses thereof
BRPI0502411A (pt) *	2005-03-31	2006-11-28	Univ Minas Gerais	processo de desenvolvimento de substáncias como inibidores potentes e seletivos de isoformas de fosfodiesterases dos tipos 1 a 5 (pde1,pde2,pde3, pde4, pde5) na base de diocleìna, fluranol ou análogos e suas composições farmacêuticas para o estudo e tratamento de doenças cardiovasculares e produtos associados
PT1888074E (pt)	2005-06-10	2012-03-01	Dong A Pharm Co Ltd	Agente para a prevenção e tratamento de doenças do fígado contendo um derivado de pirazolopirimidina
WO2007010337A2 (fr) *	2005-07-15	2007-01-25	Proxomed Medizintechnik Gmbh	Utilisation d'inhibiteurs de phosphodiesterase type 5 pour la prevention et le traitement de maladies ou de troubles, et systemes d'administration associes
EP1940389A2 (fr) *	2005-10-21	2008-07-09	Braincells, Inc.	Modulation de la neurogenese par inhibition de la pde
US7858611B2 (en)	2006-05-09	2010-12-28	Braincells Inc.	Neurogenesis by modulating angiotensin
EP2382975A3 (fr) *	2006-05-09	2012-02-29	Braincells, Inc.	Neurogénèse par modulation d'angiotensine
RU2345763C1 (ru) *	2007-04-26	2009-02-10	ФГУ "Московский научно-исследовательский институт психиатрии Федерального агентства по здравоохранению и социальному развитию"	Способ купирования и предупреждения побочных сердечно-сосудистых явлений при применении ингибиторов фосфодиэстеразы 5-го типа для лечения расстройств эрекции у мужчин

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
GB9013750D0 (en) *	1990-06-20	1990-08-08	Pfizer Ltd	Therapeutic agents
GB9401090D0 (en) *	1994-01-21	1994-03-16	Glaxo Lab Sa	Chemical compounds
CA2395558C (fr) *	1997-11-12	2007-07-17	Bayer Aktiengesellschaft	Imidazotriazinones a substitution 2-phenyle utilisees comme inhibiteurs des phosphodiesterases
HK1049834A1 (zh) *	1999-10-11	2003-05-30	辉瑞大药厂	用作磷酸二酯酶抑制剂的5-(2-取代的-5-杂环基磺酰基吡啶-3-基)-二氢吡唑并[4，3-d]嘧啶-7-酮类化合物
TWI265925B (en) *	1999-10-11	2006-11-11	Pfizer	Pyrazolo[4,3-d]pyrimidin-7-ones useful in inhibiting type 5 cyclic guanosine 3',5'-monophosphate phosphodiesterases(cGMP PDE5), process and intermediates for their preparation, their uses and composition comprising them
AU2001276607A1 (en) *	2000-08-11	2002-02-25	Pfizer Inc.	Treatment of the insulin resistance syndrome with selective CGMP PDE5 inhibitors

2002
- 2002-06-26 GB GBGB0214784.1A patent/GB0214784D0/en not_active Ceased
2003
- 2003-06-04 GT GT200300124A patent/GT200300124A/es unknown
- 2003-06-13 PA PA20038575501A patent/PA8575501A1/es unknown
- 2003-06-16 BR BR0312030-9A patent/BR0312030A/pt not_active IP Right Cessation
- 2003-06-16 PL PL03375079A patent/PL375079A1/xx not_active Application Discontinuation
- 2003-06-16 CN CN03814574XA patent/CN1662257A/zh active Pending
- 2003-06-16 JP JP2004517093A patent/JP2005531627A/ja not_active Withdrawn
- 2003-06-16 WO PCT/IB2003/002657 patent/WO2004002461A2/fr not_active Ceased
- 2003-06-16 KR KR10-2004-7021041A patent/KR20050013156A/ko not_active Ceased
- 2003-06-16 MX MXPA04012569A patent/MXPA04012569A/es unknown
- 2003-06-16 CA CA002491002A patent/CA2491002A1/fr not_active Abandoned
- 2003-06-16 RU RU2004136276/15A patent/RU2004136276A/ru not_active Application Discontinuation
- 2003-06-16 AU AU2003242895A patent/AU2003242895A1/en not_active Abandoned
- 2003-06-16 EP EP03761725A patent/EP1524996A2/fr not_active Withdrawn
- 2003-06-20 TW TW092116851A patent/TW200404546A/zh unknown
- 2003-06-24 AR ARP030102252A patent/AR040337A1/es not_active Application Discontinuation
- 2003-06-24 UY UY27863A patent/UY27863A1/es not_active Application Discontinuation
- 2003-06-24 PE PE2003000636A patent/PE20040868A1/es not_active Application Discontinuation
2004
- 2004-11-25 ZA ZA200409532A patent/ZA200409532B/en unknown
2005
- 2005-01-25 NO NO20050400A patent/NO20050400L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
TW200404546A (en)	2004-04-01
CN1662257A (zh)	2005-08-31
AU2003242895A1 (en)	2004-01-19
AR040337A1 (es)	2005-03-30
WO2004002461A3 (fr)	2004-05-13
MXPA04012569A (es)	2005-04-19
RU2004136276A (ru)	2005-09-10
CA2491002A1 (fr)	2004-01-08
GB0214784D0 (en)	2002-08-07
EP1524996A2 (fr)	2005-04-27
PE20040868A1 (es)	2004-11-25
JP2005531627A (ja)	2005-10-20
GT200300124A (es)	2004-03-17
WO2004002461A2 (fr)	2004-01-08
NO20050400L (no)	2005-03-29
UY27863A1 (es)	2003-12-31
PL375079A1 (en)	2005-11-14
ZA200409532B (en)	2006-06-28
PA8575501A1 (es)	2003-12-30
KR20050013156A (ko)	2005-02-02

Legal Events

Date	Code	Title	Description
2010-07-27	B08F	Application fees: application dismissed [chapter 8.6 patent gazette]	Free format text: REFERENTE A 5A,6A E 7A ANUIDADES
2011-08-23	B08K	Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]	Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2064 DE 27/07/2010.

Publication	Publication Date	Title
ATE346070T1 (de)	2006-12-15	Purinderivate als kinaseinhibitoren
CY1105390T1 (el)	2010-04-28	Θepαπευτικη αγωγη της πνευμονικης υπερτασης
BR0314196A (pt)	2005-07-26	Inibidores de tgf-beta
BR0312030A (pt)	2005-03-22	Combinação de inibidores de pde5 com antagonistas de receptor de angiotensina ii
MX2007002311A (es)	2008-03-10	Antagonistas del receptor de endotelina a(eta) en combinacion con inhibidores de fosfodiesterasa 5 (pdes) y usos de los mismos.
DE60332433D1 (de)	2010-06-17	Azolylaminoazine als proteinkinasehemmer
DE60332604D1 (de)	2010-07-01	Azolylaminoazine als proteinkinasehemmer
DE602005014382D1 (de)	2009-06-18	2-pyrimidinyl-pyrazolopyridin-erbb-kinaseinhibitoren
SV2002000287A (es)	2002-01-08	Uso de inhibidor de la quinasa dependiente de la ciclina para preparar una composicion farmaceutica util para tratar enfermedades neurodegenerativas
NO20076554L (no)	2008-02-19	Pyrimidin- eller triazinkondenserte, bisykliske metalloproteaseinhibitorer
CY1117108T1 (el)	2017-04-05	Ιμιδαζοτριαζινες και ιμιδαζοπυριμιδινες ως αναστολeiς κινασης
NI201000059A (es)	2010-09-13	Inhibidores de la cinasa c-fms.
IL163777A0 (en)	2005-12-18	Kinase inhibitors
BRPI0412894A (pt)	2006-10-03	tienopiridina e furopiridina inibidores de quinases
UY30297A1 (es)	2007-08-31	Inhibidores de la quinasa c-fms-i
BR0110079A (pt)	2002-12-31	Combinação de compostos orgânicos
BR0317284A (pt)	2005-11-08	Inibidores aminocianopiridina de proteìna quinase-2 ativada com proteìna quinase ativada com mitógeno
BR0311191A (pt)	2005-03-01	Combinação
GT200300231A (es)	2004-06-23	Inhibidores de hiv-integrasa, composiciones farmaceuticas y metodos para su uso
BR0307595A (pt)	2005-02-01	Uso de inibidores de pde5 tal como sildenafil no tratamento de sìndrome de ovário policìstico
EP1496897A4 (fr)	2006-05-10	Inhibiteurs de tyrosines kinases
ATE390425T1 (de)	2008-04-15	Xanthin-phosphodiesterase-v-hemmer polymorphe
EA200401137A1 (ru)	2005-04-28	Фармацевтическая композиция, содержащая ингибитор pde4 или pde3/4 и антагонист гистаминового рецептора
SE0302331D0 (sv)	2003-08-29	New use II
DOP2003000649A (es)	2003-12-30	Nueva combinacion